Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. MRVL
2. USO
3. SPY
4. BBIO
5. NVDA
6. GOOGL
7. OPCH
8. CHRW
9. AMD
10. RXO

Go back to Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's

Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments

November 12, 2012 11:02 AM EST

Sarepta Therapeutics (Nasdaq: SRPT) is trading higher Monday following a presentations by its Chief Medical Officer (CMO) at Action Duchenne, a Duchenne muscular dystrophy (DMD) event held in London this weekend.

According to reports from theStreet.com,... More

Sarepta (SRPT) to Update on Additional Eteplirsen Phase IIb Data

October 12, 2012 4:09 PM EDT

Sarepta Therapeutics (NASDAQ: SRPT) announced that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital, will present the data in an oral presentation of the abstract titled, "Results at 48 Weeks of a Phase IIb Extension Study of the... More

Sarepta Therapeutics (SRPT) Moves Higher as Ex-FDA Official Sees Accelerated Approval

October 5, 2012 10:24 AM EDT

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is moving to the highs of the session and is nearly positive... More